The Real Story Behind the Weight Loss Shots Why a gut hormone may be your doctors new favorite prescriptionand what your bodys been doing with it all along
Presented for research literature review only Riveau G et al
9 The peer companies and their ratios noted in the figure include Abbvie(1.25), Amgen(1.32), AstraZeneca(0.36), Biogen(0.71), Bristol-Myers(0.86), Eli Lilly(0.43), Gilead(0.70), GSK(0.54), JNJ(0.76), Merck(0.38), Novartis(1.25), Novo Nordisk(1.41), Pfizer(0.71), Roche(0.86), and Sanofi(0.57) 10 Lilly announces new $15 billion share repurchase program and seventh consecutive 15% dividend increase
For comparison, our semaglutide program starts at $249/month on a 6-month plan
GLP-Pro can be taken alongside GLP-Activate